Shalini Paturi, MD
Endocrinology, Diabetes & Metabolism · Mesquite, TXNPI 1215191754
Payments from drug & device makers
Across 711 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AstraZeneca$935
- Dexcom, Inc.$632
- Abbott$548
- plus $6K from 49 others
Across 11 payments — averaging $109.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1K
What the payments were for
- Food & beverage$12,17399%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$121
- FARXIGA$104
How this compares
$12,277 in reported general payments places this provider in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 547 | $696,790 |
| MounjaroTirzepatide | 350 | $446,107 |
| JardianceEmpagliflozin | 255 | $229,273 |
| Tresiba Flextouch U-100Insulin Degludec | 173 | $133,336 |
| TrulicityDulaglutide | 79 | $94,904 |
| FarxigaDapagliflozin Propanediol | 104 | $91,902 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 86 | $90,754 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 79 | $70,828 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $58,927 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $56,642 |
| Humalog Kwikpen U-100Insulin Lispro | 149 | $50,891 |
| ProliaDenosumab | 23 | $40,908 |
| TradjentaLinagliptin | 48 | $36,925 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $35,171 |
| RybelsusSemaglutide | 19 | $29,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,150 | $739,034597 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,218 | $554,211491 claims |
| Boehringer IngelheimJardiance, Tradjenta | $508 | $266,198303 claims |
| AstraZenecaFarxiga | $935 | $91,902104 claims |
| AmgenProlia | $1,359 | $40,90823 claims |
| MerckJanuvia | $242 | $15,42523 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $282 | $7,855937 claims |
| AbbVieSynthroid | $475 | $6,66399 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Mesquite
- Sumana GangiMesquite$13.2M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.